Market Place
Sourcing Support
Noveome Biotherapeutics Announces New Appointments to Board of Directors
16 Nov 2022 //
BUSINESSWIRE
Noveome Biotherapeutics, Inc. Announces New Appointments to Board of Directors
16 Nov 2022 //
BUSINESSWIRE
Noveome Receives RPD Designation and ODD for Necrotizing Enterocolitis
31 May 2022 //
TRIALSITENEWS
Noveome Bio Receives RPD Designation and ODD for Necrotizing Enterocolitis
24 May 2022 //
BUSINESSWIRE
Noveome Biotherapeutics, Inc. Commences Phase 1 Clinical Study of ST266
23 Jun 2021 //
PRNEWSWIRE
Noveome Announces Preliminary Results of its Phase 1 Clinical Trial of ST266
07 Jun 2021 //
BUSINESSWIRE
Noveome Biotherapeutics, Inc. Announces Christopher J. P. Velis as Ceo
24 May 2021 //
BUSINESSWIRE
Noveome Biotherapeutics, Inc. Makes New Appointment to Board of Directors
08 Mar 2021 //
BUSINESSWIRE
Noveome,and Walter Reed Army Institute of Research to Study Noveome’ ST266
01 Feb 2021 //
BUSINESSWIRE
Noveome Biotherapeutics, Inc. Publishes Preclinical Results Demonstrating
08 Jan 2021 //
BUSINESSWIRE
Noveome Biotherapeutics to Present at the 10th Annual Traumatic Brain
03 Nov 2020 //
BUSINESSWIRE
Noveome Biotherapeutics, Inc. Announces Publication of Preclinical Results
21 Oct 2020 //
BUSINESSWIRE
Noveome Biotherapeutics, Inc. Announces Publication of Preclinical Results
21 Oct 2020 //
BUSINESSWIRE
Noveome Biotherapeutics Announces Positive Data for Ph2 Clinical Trial of ST266
12 Jun 2020 //
BUSINESSWIRE
Noveome Biotherapeutics Announces Positive Data for Ph2 Clinical Trial of ST266
12 Jun 2020 //
BIOSPACE
Noveome Biotherapeutics Receives $4 M Grant From Commonwealth of Pennsylvania
07 May 2020 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.